Georgetown Lombardi Comprehensive Cancer Center and John Theurer Cancer Center Announce Research Initiative Developmental Funds Awards
February 8, 2016 10:25 AM
The Georgetown Lombardi Comprehensive Cancer Center (GLCCC), part of Georgetown University Medical Center, and John Theurer Cancer Center (JTCC) at Hackensack University Medical Center have announced the Research Initiative Developmental Funds Awards for 2016. Each grant provides seed money for the initiation of promising new research projects for $50,000, each funded through the “CaRe Initiative.”
“Congratulations to our 2016 Developmental Funds Awardees. This partnership between the Georgetown Lombardi Comprehensive Cancer Center and John Theurer Cancer Center is strengthened by our collaboration in research activity. Together we have an expanded set of resources and are able to offer our cancer patients greater access to treatment and care,” says Andrew L. Pecora, MD, FACP, CPE, vice president, chief innovations officer and cancer services, John Theurer Cancer Center at HackensackUMC.
The “CaRe Initiative” encourages research collaborations between GLCCC and JTCC to support promising new cancer research discoveries. The research projects involve at least one investigator from each institution.
“We are very proud of this new initiative, the 2016 awards cover some of the key topics in the rapidly changing field of oncology. They also illustrate the strength and promise of our partnership with Georgetown Lombardi Cancer Center,” said Dr. Andre Goy, M.D., M.S., chairman and director, and chief of lymphoma, John Theurer Cancer Center.
The Developmental Funds Awards for 2016 were given to the following projects:
- Intestinal Stem Cell Therapy for Gut Graft-Versus-Host Disease – primary investigators,
Rena Feinman, JTCC; and Steven Singer, GLCCC
- STAG2 Expression as a Biomarker for the Clinical Behavior of Non-Muscle Invasive Papillary Urothelial Carcinoma of the Bladder – primary investigators, Ciaran Mannion, JTCC; and Todd Waldman, GLCCC
- Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant after Induction for Patients with Multiple Myeloma – primary investigators, Noa Biran, JTCC; and Roxanne Jensen, GLCCC
- Downregulating Osteoblastic N-Cadherin to Improve Metastatic Prostate Cancer Sensitivity to Drug Treatment – primary investigators, Jenny Zilberberg, JTCC; Chris Albanese, GLCCC; and Shahin Assefina, GLCCC
- An Exercise RCT to Reduce Fatigue in Women Undergoing Radiation Treatment for Breast Cancer – primary investigators, Brett Lewis, JTCC; and Lucille Adams-Campbell, GLCCC
- Endocrine Disruptors, Obesity, and Breast Density among Perimenopausal Women – primary investigators, Gail Starr, JTCC; Erin Ihde, JTCC; and Chiranjeev Dash, GLCCC
- Inositol Tris-Pyrophosphate (ITPP) as a Single Agent Therapy for Syngeneic Orthotopic Triple Negative 4T1 Breast Cancer in Immunocompetent BALB/c Mice: Impact on Survival, Hypoxia, and Autophagy – primary investigators, Sujatha Iyengar, JTCC; and Robert Clarke, GLCCC
- Lipid Peroxidation-Derived DNA Adduct in Increased Risk of Colon Cancer with MMR-Deficiency – primary investigators, Kar Fai (David) Chow, JTCC; and Fung-Lung Chung, GLCCC
About John Theurer Cancer Center at Hackensack University Medical Center
John Theurer Cancer Center is among the nation’s top 50 U.S. News & World Report Best Hospitals for Cancer – and the highest ranked in New Jersey. As New Jersey's largest and most comprehensive cancer center, JTCC is dedicated to the care, of patients with all types of cancer, from diagnosis to survivorship. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Each of the 14 specialized divisions feature a team of medical, research, nursing and support staff with specialized expertise that translates into the most advanced, focused and compassionate care possible.
About Hackensack University Medical Center
HackensackUMC, a 775- bed nonprofit teaching and research hospital located in Bergen County, NJ, is the largest provider of inpatient and outpatient services in the state. Founded in 1888 as the county’s first hospital, it is the flagship hospital of Hackensack University Health Network, one of the largest health networks in the state comprised of 1,717 beds, more than 10,000 team members and 3,300 credentialed physicians. HackensackUMC was listed as the number one hospital in New Jersey in U.S. News & World Report’s 2015-16 Best Hospital rankings - maintaining its place atop the NJ rankings since the rating system was introduced. It was also named one of the top four New York Metro Area hospitals. HackensackUMC is the only hospital in New Jersey, New York and New England to be named one of Healthgrades America's 50 Best Hospitals™ nine consecutive years, and receive the Healthgrades Distinguished Hospital Award for Clinical Excellence™ 13 years in a row. The medical center is one of the top 25 green hospitals in the country according to Practice Greenhealth, and received 24 Gold Seals of Approval™ by The Joint Commission – more than any other hospital in the country. It was the first hospital in New Jersey and second in the nation to become a Magnet® recognized hospital for nursing excellence; receiving its fifth consecutive designation in 2014. HackensackUMC has created an entire campus of award-winning care, including: the John Theurer Cancer Center; the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Women’s and Children’s Pavilion, which houses the Joseph M. Sanzari Children’s Hospital and Donna A. Sanzari Women’s Hospital, which was designed with The Deirdre Imus Environmental Health Center and listed on the Green Guide’s list of Top 10 Green Hospitals in the U.S. HackensackUMC is the Hometown Hospital of the New York Giants and the New York Red Bulls and is Official Medical Services Provider to The Barclays PGA Golf Tournament. It remains committed to its community through fundraising and community events. To learn more, visit: www.HackensackUMC.org.